Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC cut its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 8.3% during the second quarter, HoldingsChannel.com reports. The firm owned 81,758 shares of the biotechnology company’s stock after selling 7,367 shares during the period. Squarepoint Ops LLC’s holdings in Oramed Pharmaceuticals were worth $210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Murchinson Ltd. increased its position in Oramed Pharmaceuticals by 31.4% during the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock valued at $4,028,000 after buying an additional 329,495 shares in the last quarter. Virtu Financial LLC acquired a new stake in Oramed Pharmaceuticals in the first quarter worth about $68,000. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 10,774 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Oramed Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ORMP. StockNews.com raised shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 4th. HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $2.38 on Friday. The business’s 50-day simple moving average is $2.38 and its two-hundred day simple moving average is $2.42. The company has a market cap of $96.70 million, a PE ratio of 9.15 and a beta of 1.77. Oramed Pharmaceuticals Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. As a group, analysts predict that Oramed Pharmaceuticals Inc. will post 0.24 EPS for the current fiscal year.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.